Effects of Rituximab on the Development of Viral and Fungal Infections in Renal Transplant Recipients
Table 1
Demographics and transplant characteristics.
Variable
RTX
No RTX
value
Age, years
0.42
Race
Caucasian, % ()
65 (36)
40 (155)
<0.001
African American, % ()
18 (10)
27 (104)
0.15
Male gender, % ()
42 (23)
61 (235)
0.008
Diabetes history, % ()
24 (13)
36 (137)
0.08
Concurrent viral diseasea % ()
4 (2)
6 (24)
0.42
Peak PRA, %
<0.001
Deceased donor, % ()
45 (25)
38 (145)
0.26
Retransplant, % ()
24 (13)
7 (27)
<0.001
Pretransplant dialysis, years
0.27
Kidney-pancreas recipient, % ()
9 (5)
7 (26)
0.54
CMV donor+/recipient− serostatus
22 (12)
17 (67)
0.43
Delayed graft function
9 (5)
9 (36)
0.97
Abbreviations—PRA: panel reactive antibodies; CMV: cytomegalovirus.
aConcurrent viral disease includes history of hepatitis B, hepatitis C, or human Immunodeficiency virus.
